Related Experiment Videos
Detection of an inhibiting activity for osteoclast bone resorption from human prostatic cancer cells
1Regional Bone Center, Helen Hayes Hospital, New York State Department of Health, West Haverstraw 10993, USA.
Abstract:
An inhibiting activity for isolated osteoclasts and bone resorption was demonstrated in culture supernatants from androgen-independent, but not androgen-dependent, human prostatic cancer cell lines. It causes a dose-dependent osteoclast inhibition as quantified with a bone resorbing pit formation assay. The constitutively released activity was determined to be protein (>50 kDa) distinct from some of the known cytokines in bone resorption. The activity does not affect osteoclast morphology and viability. Time-lapse video microscopy revealed an osteoclast motility increase, disrupting their anchorage to the bone and resorbing processes. The association of the activity with androgen-independent cancer cells that disrupt bone remodeling is discussed.
Insights
Androgen-independent prostate cancer cells release a protein that inhibits bone resorption by increasing osteoclast motility. This discovery offers new insights into bone remodeling disruption in advanced prostate cancer.
Area of Science:
- Oncology
- Cell Biology
- Bone Biology
Background:
- Prostate cancer frequently metastasizes to bone, leading to pathological fractures and hypercalcemia.
- Androgen-independent prostate cancer (AIPC) is associated with more aggressive disease and poorer prognosis.
- Bone remodeling is a tightly regulated process involving osteoblasts and osteoclasts, which can be disrupted by cancer cells.
Purpose of the Study:
- To investigate the mechanism by which androgen-independent prostate cancer cells affect bone resorption.
- To identify and characterize a novel activity released by AIPC that influences osteoclast function.
Main Methods:
- Culture supernatants from androgen-dependent and -independent human prostate cancer cell lines were analyzed.
- Osteoclast inhibition was quantified using a bone resorbing pit formation assay.
- Protein characterization involved size exclusion (>50 kDa) and assessment of effects on osteoclast morphology, viability, and motility via time-lapse video microscopy.
Main Results:
- Culture supernatants from AIPC, but not androgen-dependent cells, demonstrated dose-dependent inhibition of osteoclast bone resorption.
- The inhibitory activity is a constitutively released protein (>50 kDa), distinct from known bone resorption cytokines.
- The activity did not affect osteoclast morphology or viability but significantly increased osteoclast motility, disrupting bone anchorage.
Conclusions:
- Androgen-independent prostate cancer cells secrete a novel protein that disrupts bone remodeling by impairing osteoclast function through increased motility.
- This finding highlights a potential mechanism for bone metastases in AIPC and suggests therapeutic targets for managing bone complications.